CD12681 is a Potent RORγ Inverse Agonist, Preclinical Candidate for the Topical Treatment of Psoriasis. References: Ouvry G, Atrux-Tallau N, Bihl F, Bondu A, Bouix-Peter C, Carlavan I, Christin O, Cuadrado MJ, Defoin-Platel C, Deret S, Duvert D, Feret C, Forissier M, Fournier JF, Froude D, Hacini-Rachinel F, Harris CS, Hervouet C, Huguet H, Lafitte G, Luzy AP, Musicki B, Orfila D, Ozello B, Pascau C, Pascau J, Parnet V, Peluchon G, Pierre R, Piwnica D, Raffin C, Rossio P, Spiesse D, Taquet N, Thoreau E, Vatinel R, Vial E, Hennequin LF. Discovery and Characterization of CD12681, a Potent RORγ Inverse Agonist, Preclinical Candidate for the Topical Treatment of Psoriasis. ChemMedChem. 2018 Feb 20;13(4):321-337. doi: 10.1002/cmdc.201700758. Epub 2018 Feb 6. PubMed PMID: 29327456.

纯度：≥98%

CAS：1952239-59-6